Mathematical model of uptake and metabolism of arsenic(III) in human hepatocytes - Incorporation of cellular antioxidant response and threshold-dependent behavior by Stamatelos, Spyros K et al.
RESEARCH ARTICLE Open Access
Mathematical model of uptake and metabolism of
arsenic(III) in human hepatocytes - Incorporation
of cellular antioxidant response and threshold-
dependent behavior
Spyros K Stamatelos
1,2, Christopher J Brinkerhoff
1, Sastry S Isukapalli
1, Panos G Georgopoulos
1*
Abstract
Background: Arsenic is an environmental pollutant, potent human toxicant, and oxidative stress agent with a
multiplicity of health effects associated with both acute and chronic exposures. A semi-mechanistic cellular-level
toxicokinetic (TK) model was developed in order to describe the uptake, biotransformation and clearance of
arsenical species in human hepatocytes. Notable features of this model are the incorporation of arsenic-glutathione
complex formation and a “switch-like” formulation to describe the antioxidant response of hepatocytes to arsenic
exposure.
Results: The cellular-level TK model applies mass action kinetics in order to predict the concentrations of trivalent
and pentavalent arsenicals in hepatocytes. The model simulates uptake of arsenite (iAs
III) via aquaporin isozymes 9
(AQP9s), glutathione (GSH) conjugation, methylation by arsenic methyltransferase (AS3MT), efflux through multidrug
resistant proteins (MRPs) and the induced antioxidant response via thioredoxin reductase (TR) activity. The model
was parameterized by optimization of model estimates for arsenite (iAs
III), monomethylated (MMA) and
dimethylated (DMA) arsenicals concentrations with time-course experimental data in human hepatocytes for a time
span of 48 hours, and dose-response data at 24 hours for a range of arsenite concentrations from 0.1 to 10 μM.
Global sensitivity analysis of the model showed that at low doses the transport parameters had a dominant role,
whereas at higher doses the biotransformation parameters were the most significant. A parametric comparison of
the TK model with an analogous model developed for rat hepatocytes from the literature demonstrated that the
biotransformation of arsenite (e.g. GSH conjugation) has a large role in explaining the variation in methylation
between rats and humans.
Conclusions: The cellular-level TK model captures the temporal modes of arsenical accumulation in human
hepatocytes. It highlighted the key biological processes that influence arsenic metabolism by explicitly modelling
the metabolic network of GSH-adducts formation. The parametric comparison with the TK model developed for
rats suggests that the variability in GSH conjugation could have an important role in inter-species variability of
arsenical methylation. The TK model can be incorporated into larger-scale physiologically based toxicokinetic (PBTK)
models of arsenic for improving the estimates of PBTK model parameters.
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A r s e n i ci san a t u r a l l yo c c u r ring metalloid, abundant in
the earth’s crust and a component of more than 245
minerals [1]. Exposure to arsenic has been associated
with cancers of the liver, bladder, skin and lung [2,3].
Epidemiological studies in Taiwan, Bangladesh and India
have reported adverse health effects associated with
chronic arsenic exposure including; chronic obstructive
pulmonary disease, non-cirrhotic portal fibrosis, hyper-
tension and ischeamic heart disease [4]. The risk of
developing serious diseases from chronic exposure to
inorganic arsenic in drinking water prompted the US
Environmental Protection Agency (EPA) to lower the
maximum contamination level (MCL) for arsenic in
drinking water to 10 ppb [5].
There are two biologically important arsenic valence
states: arsenite (As(OH)
3, iAs
III) and arsenate (AsO(OH)
3,
iAs
V). Inorganic arsenic in water is largely in the form of
arsenate; it is negatively charged at physiological pH and
slowly taken up by cells [6]. Arsenate is rapidly converted
to arsenite in vivo [7] which is taken up by cells much
more quickly than arsenate [8]. Methylation of arsenicals
facilitates their excretion from the cell and therefore was
long considered a detoxification process, but recent evi-
dence indicates that monomethylated (MMA) and
dimethylated (DMA) arsenicals have many toxic effects
including increased oxidative stress [9], chromosomal
aberrations (CA), and oxidative DNA damage [10-12]. In
hepatocytes, trivalent monomethylated arsenicals
(MMA
III) inhibit the activity of thioredoxin reductase
(TR), which is a critical antioxidant enzyme controlling
the cellular redox balance [13,14].
Uptake and efflux of arsenicals occur primarily through
transporter proteins. Uptake of iAs
III in hepatocytes and
efflux of MMA
III to blood take place through aquaporin
isozymes 9 (AQP9), a family of membrane-spanning pro-
teins that facilitate movement of solutes down their con-
centration gradient. AQP9 channels are expressed at high
concentrations in liver cells and have been shown to trans-
port iAs
III when expressed both in Saccharomyces cerevi-
siae (yeast) and in Xenopus oocytes [15-17]. Another class
of transmembrane proteins facilitating the transport of
iAs
III and MMA
III across the cellular membrane of hepa-
tocytes is glucose transporters and especially GLUT2
which is highly expressed in the liver [18,19]. Glutathione
conjugated arsenicals are exported to the extracellular
space via multidrug resistant proteins (MRPs) and multi-
drug resistant P-glycoproteins (PGPs)which are ATP-
binding cassette (ABC) transporters that export solutes
against their concentration gradient [19-21].
Methylation of inorganic arsenic takes place primarily in
the liver and specifically in hepatocytes via enzymatic cata-
lysis by arsenic methyltransferase (AS3MT), previously
known as Cyt19, producing both mono- and dimethylated
arsenicals [22-25]. Two biochemical pathways have been
proposed for methylation of arsenates with a key differ-
ence in the substrate for AS3MT methylation: (a) a classi-
cal process of alternating steps of reduction and oxidative
methylation where iAs
III and MMA
III are the substrates
and the methylation can happen in the presence or
absence of GSH [26] and (b) a process of GSH conjugation
and reductive methylation where thiol-bound arsenicals
(arsenic triglutathione - ATG, monomethylarsenic diglu-
tathione - MADG) are the substrates [27,28]. GSH has a
stimulatory role in both methylation pathways either as a
reductant or in direct conjugation with arsenicals [29].
Arsenic activates the redox sensitive transcription fac-
tor Nuclear Factor -E2- related factor 2 (Nrf2) causing
its increased nuclear translocation and Nrf2 binding to
the Antioxidant Response Element (ARE) [30,31].
Arsenic activates Nrf2 in a different manner when com-
pared to other compounds such as sulforaphane (SF)
and tert-butylhydroquinone (tBHQ) enhancing the inter-
action of specific subunits of the E3 ubiquitin ligase
[32]. It has been suggested that hepatocytes exhibit an
“on-switch” antioxidant behavior when exposed to
increasing arsenic doses [33], possibly a result of this
Nrf2 activation.
In this study, a cellular-level semi-mechanistic TK
model was developed for predicting intra-cellular con-
centrations of different arsenicals (trivalent and pentava-
lent) in hepatocytes. Currently, the only published
cellular-level TK model for the uptake, biotransforma-
tion and efflux of arsenicals is the Easterling et al. [34]
model schematically shown in Figure 1; they demon-
strated the relative importance of transport processes
affecting the accumulation of arsenicals in rat hepato-
cytes [34]. However, a TK model for humans is needed
since the inherent variation of arsenic metabolic capa-
city across various organisms complicates the extrapola-
tion of rat TK model to humans. Therefore, the
mathematical model presented here was developed for
humans and parameterized based on data from human
hepatocytes.
Methods
The human TK model applies mass action kinetics in
order to predict the concentrations of trivalent and
pentavalent arsenicals including arsenite (iAs
III),
monomethylated (MMA), and dimethylated arsenicals
(DMA) in human hepatocytes. This TK model takes
into account processes such as influx, efflux, methyla-
tion, oxidation and glutathione conjugation of arseni-
cals. Moreover, it accounts for induced cellular
antioxidant response due to arsenic exposure through
a “switch-like” mechanism that alters the model
response above a specific threshold concentration
[35].
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et al. model [34], in terms of the ability to fit to data of
arsenic retention and methylation in human hepato-
cytes. This comparison aims to highlight the advantages
of developing biologically relevant TK models based on
data acquired from human cells. Further comparison of
these two models in terms of their estimated parameter
values aim to study the major intracellular kinetic pro-
cesses that contribute to the differences in metabolism
between humans and rats.
Model Development
The semi-mechanistic TK model describes arsenic trans-
port across the cellular membrane and arsenic metabo-
lism in hepatocytes according to the metabolic reaction
cascade proposed by Hayakawa et al. [27] (Figure 2).
Figure 3 presents a schematic depiction of the constitu-
ents of the TK model that are also explained in Table 1.
These constituents include chemical species and
enzymes, and the interactions among them. Fundamental
assumptions made in the formulation of the TK model
are:
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Figure 2 A new metabolic pathway of inorganic arsenic
biotransformation via arsenic-GSH complexes formation. This
pathway includes two separate branches of arsenic
biotransformation: MADG ® MMA
III ® MMA
V and MADG ® DMAG
® DMA
III ® DMA
V (Source: Hayakaya et al. [27]).
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Figure 3 Schematic depiction of the cellular level TK model for
human hepatocytes showing the major components. Green
squares represent extracellular amounts of arsenicals, while red
squares represent intracellular amounts. Ovals represent activities of
proteins (AQP9, TR, MT1, MT2, MRPa and MRm) and GSH (GS-Pm,
GS-Pd). Arrows and hammerheads indicate activation and inhibition
respectively.
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Figure 1 Schematic depiction of the cellular level TK model for
rat hepatocytes. The solid lines that cross the cellular membrane
(oval) represent transport processes, while the solid lines within the
oval represent biotransformation. The dashed line represents the
inhibitory effect of iAs
III on the second methylation reaction (MMA
to DMA) (Source: Easterling et al. [34])
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Notation Parameter Value Units Description
1k ATG int 0.25 1/min Rate of production of ATG
2k MADG int 90 1/min Rate of production of MADG
3k DMAG 0.0122 1/min Rate of production of DMAG
4k oxd 33.254 1/min Rate of oxidation of DMA
III
5k oxm 0.2375 1/min Rate of oxidation of MMA
III
6k iAs
III
int 320 1/min Rate of production of iAs
III
7k MMA
III
int 1200 1/min Rate of production of MMA
III
8n 3 8 - Hill coefficient of inhibition of MMA
III production
9K d 3 12.94 μM Dissociation constant of inhibition of MMA
III
10 fGSHm 0.992 - Coefficient of inhibition of MADG hydrolysis
11 kgin 704.96 1/min Rate of GSH production increase
12 kDMA
III
int 0.8472 1/min Rate of production of DMA
III
13 fGSHd 0.9988 - Coefficient of inhibition of DMAG hydrolysis
14 Vmaxt2 1.237 pmol/min Maximal rate of MADG efflux
15 Kmt2 19.47 μM Half saturation constant of MADG efflux
16 kmin 512.27 1/min Rate of upregulation of MRP
17 kss 4.26 1/min Steady state rate of efflux of iAs
III
18 τe 10 min Time constant of AQP9 inactivation
19 k0 4.2 1/min Initial rate of efflux of iAs
III
20 kinf 1.613 1/min Influx of iAs
III
21 kMMAext 0.0006 1/min Rate of efflux of MMA
22 fm 0.2 - Coefficient of efflux of MMA
23 Vmaxt1 0.35 pmol/min Maximal rate of ATG efflux
24 Kmt1 2.3 μM Half saturation constant of ATG efflux
25 kDMAext 0.002 1/min Rate of efflux of DMA
26 fd 3 - Coefficient of efflux of DMA
27 Vmaxm 50 pmol/min Maximal rate of ATG methylation
28 Kmm 9.32 μM Half saturation constant of ATG methylation
29 n1 1.22 - Hill coefficient of ATG methylation
30 Kd1 0.315 μM Dissociation constant of ATG methylation
31 Kim 1.53 μM Inhibition constant of ATG methylation
32 Kid 1 μM Inhibition constant of MADG methylation
33 Vmaxd 8 pmol/min Maximal rate of MADG methylation
34 Kmd 0.034 μM Half saturation constant of MADG methylation
35 n2 1.83 - Hill coefficient of MADG methylation
36 Kd2 2.33 μM Dissociation constant of MADG methylation
37 kain 1.64 1/min Rate of AS3MT efficiency increase
38 fA 50 - Coefficient of MADG methylation inactivation
39 kTR 0.99 1/min Rate of TR signaling
40 kTRinact 987.13 1/min Rate of TR inactivation
41 TRC 15 - Constant of TR inactivation
42 N 1.75 - Hill coefficient of TR inactivation
43 TR0 9.27 1/min Steady state value of TR activity
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pores is governed by their electrochemical potential,
and can be described through an ion channel con-
ductance-based formulation.
2) The oxidative stress mediated response of hepato-
cytes to arsenite exposure exhibits a “switch-like”
behavior, and the upregulation of enzyme activities
can be described through an approximate step func-
tion at a threshold concentration.
3) The methylation reactions are influenced by coop-
erativity phenomena as well as substrate inhibition,
and can be described through a hybrid approach of
Hill and Michaelis-Menten kinetics.
4) The GSH-bound hydrolysis and clearance of
methylated arsenicals exhibit a threshold-dependent
behavior, and can be described using a sigmoidal
function.
5) Concentrations of arsenicals are uniform within
the hepatocytes as well as the extracellular medium
6) All hepatocytes in the system have identical prop-
erties, are uniformly distributed in the medium, and
are exposed to the same extracellular concentrations
of arsenicals.
Uptake of arsenite by hepatocytes via AQP9s [36] is
governed by their electrochemical potential across the
cellular membrane (for simplicity we refer to AQP9s as
being the ensemble of the activity of both AQP9 and
GLUT2 channels). The conductance-based formulation
for ion channels proposed in the Hodgkin-Huxley
model [37] is used here to describe the regulation of
arsenite flux by AQP9s (Equations 1-2). Specifically, the
inactivation of AQP9 subunit gates during iAs
III influx
is described by Equation 1b, which expresses the
increased probability of these gates closing as more
transport across the gates occurs.
d(iAs )
dt
k (iAs ) AQP9 (iAs )
k(
III
int
inf
III
ext
III
int
ATGint
=× − ×
−× i iAs ) k (ATG)
III
int iAsIII
int
int +×
(1a)
AQP9 [k (k k ) (1-e )] 0S S 0
t
e =+ −×
−
 (1b)
d(iAs )
dt
AQP9 (iAs ) k (iAs )
III
ext III
int inf
III
ext =× − × (2)
Where, kinf represents the mass transfer coefficient for
influx of arsenite in hepatocytes; k ATGint represents the
rate constant for arsenite conjugation with GSH to form
ATG catalyzed by the Glutathione S-Transferase (GST)
family of enzymes; k
iAsIII
int
is the rate constant for
hydrolysis of ATG (reciprocal to conjugation); kSS is the
steady state rate constant for efflux of arsenite that is
attained at long time periods; k0 i st h er a t ec o n s t a n t
describing the basal activity of AQP9; and τe is the time
constant governing the regulation of AQP9 gates.
Thioredoxin (Trx) Reductase (TR) is the enzyme that
catalyzes the reduction of Trx. Trx is a critical antioxi-
dant protein and an important reductant in the methyla-
tion of arsenic by AS3MT [38]. The inactivation of TR
by MMA
III leads to signals that account for two differ-
ent phenomena: the induction of GSH and ABC trans-
porters via a redox sensitive activation of the cellular
antioxidant response Nrf2 nuclear receptor pathway
[14,39] and the decreased methylation capacity of
A S 3 M T .I nt h i ss t u d yt h em a i nf o c u si so nM R P sa sa n
efflux mechanism of arsenicals since it has been
reported that they are regulated by Nrf2 [40,41]. The
inactivation is modeled using principles of indirect
response model theory [42,43] via the threshold-depen-
dent parameter:S
[iAs ] threshold
threshold
III
init =
− . Parameter S
depends on the initial exposure concentration of
arsenite, (iAs
III)init and a threshold concentration. The
value of S is zero when arsenite doses are below the
threshold concentration, and gradually increases with
greater arsenite doses. The following equations describe
this reaction cascade:
dTR
dt
k (TR TR)
S
TR
 
kH
TR 0
C
TRinact TR
=× −−
××
(3a)
H
[MMA ]
(IC ) [MMA ]
TR
III N
TR
N III N =
+
(3b)
dGSH
dt
k
1
TR
kG S H gin gdeg =× − × (4a)
k
k
TR
gdeg
gin
0
= (4b)
dMRP
dt
k
1
TR
kM R P min mdeg =× − × (5a)
k
k
TR
mdeg
min
0
= (5b)
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dt
kT R k A S 3 M T ain adec =× − × (6a)
kk T R adec ain 0 =× (6b)
where, kTR is the first-order rate constant controlling
the activity of TR; TR0 is the baseline activity value of
TR; k TRinact is the first-order rate constant for TR
inactivation; TRc is a dimensionless inactivation con-
stant; N is the Hill coefficient for enzyme inactivation
from MMA
III; k gin, kmin and kain are the rate con-
stants governing of the activities of GSH, MRP and
AS3MT, k gdeg, kmdeg and kadec are the correspond-
ing first-order decay constants.
Methylation reactions of arsenic in the liver have been
modeled in published cellular-level and whole-body
PBTK models with classical Michaelis-Menten kinetics
[34,44-46]. Alternatives include cooperativity models such
as the classical Hill-type formulation and the more
mechanistic Monod-Wyman-Changeux (MWC) model
[47]. In preliminary analyses, these formulations were
unable to explain the time course patterns of arsenic
retention and methylation in human hepatocytes (results
not shown). Therefore, an alternative, non-classical formu-
lation was used in the TK model. In this model, the
AS3MT is assumed to exhibit cooperativity and the
methylation reaction rate is assumed to exhibit hysteretic
sigmoidal behavior as per Frieden [48]. In this formulation,
the cooperativity is described by a Hill-type formulation
for Vmax that is dependent on the total ATG present in
the system. The formulation accounts for the constitutive
influence of GSH in the methylation reaction cascade and
its role in the increase of Vmax. Moreover this Hill-type
formulation for Vmax accounts for a possible colocalization
of thiol-containing proteins that interact with GSH (e.g.
GSTP1), MRPs and AS3MT in hepatocytes. This colocali-
zation would control not only the production and clear-
ance of ATG but methylation activity as well [49,50].
Previous studies have suggested that exposure of
human hepatocytes to elevated doses of iAs
III (0.4 -
4 μΜ) markedly reduced the production of DMAs while
at the same time increased the yields of MMAs [51].
Therefore, it is assumed here that the AS3MT inactiva-
tion signal (Equation 6) affects only the second methyla-
tion reaction rate (Equation 8a).
MADG MT  
[ATG]
1
[ATG]
Km
(1
[ATG]
K
)
ui 1
int
int
m
int
im
=
×
+× +
(7a)
MT
([ATG] [ATG] )
(K ) ([ATG] [ATG] )
 
V
1
int ext
n1
d1
n1
int ext
n1
m
=
+
++
×
a axm
mm K
(7b)
DMAG MT  
[MADG]
1
[MADG]
Km
(1
[ATG]
K
)
ui 2
int
int
d
int
id
=
×
+× +
(8a)
MT
AS3MT
f tanh(S) 1
 
([ATG] [ATG] )
(K ) ([ATG]
2
A
int ext
n2
d2
n2
=
+ ×
×
+
+ i int ext
n2
maxd
md [ATG] )
V
K +
×
(8b)
where, MADGui and DMAGui are the rates of arsenic
methylation for the first ands e c o n dm e t h y l a t i o nr e a c -
tions respectively. Vmaxm and Vmaxd are the maximal
rates of the first and second methylation reactions
respectively; Kmm and Kmd are the half-saturation
constants for the methylation reactions; Kim and Kid are
the uncompetitive inhibition constants for the respective
reactions n1,n 2 are the Hill coefficients; Kd1 and Kd2
are the dissociation constants influencing the sigmoidal
change in Vmaxm and Vmaxd;a n df A is a coefficient of
the second methylation reaction inactivation.
MADG hydrolysis reaction is modeled using a
“switch-like” formulation. For doses below the threshold,
a Hill-type formulation is used (Equation 9b). Above the
threshold concentration, the rates of hydrolysis of
MADG and DMAG to MMA
III and DMA
III, respec-
tively, are assumed to be attenuated due to oxidative
stress-induced GSH upregulation (Equations 9-10). On
the other hand, this non-linear behavior may result in
an increase or a decrease of GSH depending on the con-
centration of iAs
III and the duration of exposure. The
non-linear sigmoid function tanh(S) is used here to
describe this “switch-like” behavior; this formula has
been previously used [52] in a neurocomputational
model to describe the non-linear threshold-dependent
behavior of neuronal firing rate.
HD [1-f tanh(S)] 
(1 H tanh(S) H ) 
GS-P (MADG)
mG S H m
GSH GSH
m
=×
×− + ×
×× i int
(9a)
GS-P
 k
GSH
m
MMAIII
int = (9b)
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([ATG] [ATG] )
(Kd ) ([ATG] [ATG] )
GSH
int ext
n3
3
n3
int ext
n3
=
+
++
(9c)
HD [1-f tanh(S)] GS-P
 (DMAG)
dG S H d d
int
=××
×
(10a)
GS-P
 k
GSH
d
DMAIII
int = (10b)
where HDm and HDd are the rates of hydrolysis of
MADG and DMAG respectively. k
MMAIII
int
is the reac-
tion rate constant for MADG hydrolysis (MMA
III pro-
duction); fGSHm is the coefficient of inhibition of
MADG hydrolysis; n3 and Kd3 are the Hill coefficient
and dissociation constant, respectively, for the inhibition
term; k
DMAIII
int
is the reaction rate constant for
DMAG hydrolysis (DMA
III production); and fGSHd is
the coefficient of inhibition of DMAG hydrolysis.
Efflux of GSH (or protein) -bound arsenic adducts
(ATG, MADG) is assumed to take place via multidrug
resistant proteins (MRPs), and is described by classical
Michaelis-Menten kinetics. Since MADG is a substrate
in the dimethylation reaction (Equation 8a), its efflux
rate is assumed to be affected by MRP levels [51].
d(ATG)
dt
MRP
[ATG]
1
[ATG]
K
ext
a
int
int
mt
=
+
×
1
(11a)
MRP
V
K
a
max t
mt
= 1
1
(11b)
d(MADG)
dt
MRP
[MADG]
1
[MADG]
K
ext
m
int
int
mt2
=×
+ (12a)
MRP MRP
V
K
m
max t2
mt2
=× (12b)
d(MMA )
dt
[(f -1) tanh(S) 1] 
k (MMA )
V
ext
m
MMAext
V
int
=×+
××
(13)
d(MMA )
dt
[(f -1) tanh(S) 1] 
k (MMA )
III
ext
m
MMAext
III
int
=×+
××
(14)
d(DMA)
dt
[(f -1) tanh(S) 1] 
k ( D M A )
V
ext
d
DMAext
V
int
=× +
××
(15)
d(DMA)
dt
[(f -1) tanh(S) 1] 
k( D M A )
III
ext
d
DMAext
III
int
=× +
××
(16)
where, VK maxt1
mt1
, and VK maxt2
mt2
, are the
Michaelis constants of the biophysical clearance of ATG
and MADG, respectively; kMMAext and kDMAext are
the rate constants of MMA and DMA clearance, respec-
tively; fm and fd are the dimensionless coefficients of
clearance of the respective processes affecting the maxi-
mal efflux.
The remaining biotransformation reactions include a
series of methylation, glutathione conjugation and oxi-
dation reactions [27] (Equations 17-23).
d(ATG)
dt
k( i A s ) k
(ATG) MADG
int
ATGint
III
int iAsIII
int
int ui
=× −
×− − −
d(ATG)
dt
ext
(17)
d(MADG)
dt
MADG  
k (MMA )  
DMAG HD
d(MA
int
ui
MADGint
III
int
ui m
=
+×
−− −
D DG)
dt
ext
(18)
d(MMA )
dt
HD (k k ) 
(MMA )
d(MMA )
III
int
mM A D G int oxm
III
int
III
e
=− +
×− x xt
dt
(19)
d(MMA )
dt
k (MMA )  
d(MMA )
dt
V
int
oxm
III
int
V
ext
=×
−
(20)
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dt
DMAG k  
(DMA ) HD
ui DMAG
III
int d
=+
×−
(21)
d(DMA )
dt
HD (k k ) 
(DMA )
d(DMA)
d
III
int
dD M A G o x d
III
int
III
ext
=− +
×−
t t
(22)
d(DMA )
dt
k( D M A )  
d(DMA)
dt
V
int
oxd
III
int
V
ext
=×
−
(23)
where kMADGint is the rate constant of MADG pro-
duction catalyzed by the Glutathione S-Transferase
(GST) family of enzymes; koxm is the rate constant
for MMA
III oxidation; kDMAG i st h er a t ec o n s t a n tf o r
DMAG production catalyzed by the Glutathione
S-Transferase (GST) family of enzymes and koxd is the
rate constant for DMA
III oxidation. It has been sug-
gested for this biotransformation pathway that trivalent
arsenicals mostly bound to thiol-containing proteins are
conjugated with GSH and methylated in the presence of
arsenic methyltransferase (AS3MT) [28]. Therefore, the
parameters kATGint, kMADGint and kDMAG indirectly
represent the binding of trivalent arsenicals to thiol-
containing proteins in the TK model.
The TK model has been implemented in MATLAB;
the system of ODEs comprising the TK model is
solved numerically using the stiff solver ode15s.F i r s t ,
the model parameters corresponding to low doses (i.e.
below the threshold) were estimated using time course
in vitro measurements of arsenicals following expo-
sures to 0.1 μMi A s
III ,f r o mS t y b l oet al. [51]; it was
assumed that at this dose, the hepatocytes exhibit no
induced antioxidant response. Subsequently, model
parameters corresponding to a wider range of doses
(i.e. including both low-dose and high-dose behavior)
were estimated using dose-response data (for doses
ranging from 0.1 - 10 μM) reported by Drobna et al.
[53]. The Drobna dataset includes measured concen-
trations of iAs
III,M M A ,a n dD M Ai np r i m a r yc u l t u r e d
human hepatocytes after 24 h exposure to iAs
III (data
for hepatocytes from 8 donors). For this case study,
data on hepatocytes from one donor (white female,
aged in the 60 s, Donor C) [53] were used, since this
donor had similar characteristics to the human donor
in the study by Styblo et al. [51]. The deterministic
optimization function fmincon was used for parameter
estimation in both cases.
Sensitivity analysis
Sensitivity analysis provides estimates of how variation
of model’s output can be apportioned to different
sources of variation in model parameters. This quantity
is given by the formula:
var E(Y/P)
var(Y)
D
D
P P []
= (24)
where Y denotes model output and P denotes the vec-
tor of model parameters; DP and D illustrate the partial
and total variance of the model output due to variation
in model parameters according to assigned statistical
distributions.
T h eF o u r i e rA m p l i t u d eS e n s i t i v i t yT e s t( F A S T )
decomposes the total variance of model output (D) into
terms of increasing dimensionality. FAST computes the
Total Sensitivity Indices (TSI), which account not only
for the variance due to individual parameters (Di), but
also estimate the variance due to interaction among
parameters (Dij, Dijk, etc.) The total variance for n
dimensions is given by
D D D ... D i
i=1
n
ij
j=i+1
n
n
i=1
n
=+ + + ∑∑ ∑ 12 , ,.., (25)
The model parameters were assumed to be normally
distributed with a coefficient of variation up to 10%; for
some parameters, the coefficient of variation was 1%. Ten
thousand (10,000) samples were generated and the nor-
mal distributions for all parameters were truncated at 1%
and 99% (approximately three standard deviations from
the mean value). Three model outputs were selected for
the sensitivity analysis: Areas under the Curve (AUCs) of
total retention of MMA, DMA and iAs
III in human hepa-
tocytes. The SIMLAB modeling platform [54] was used
to perform the global sensitivity analysis.
Comparison with the TK modeling formulation for rat
hepatocytes
The TK model presented here was also compared with
results from a published model for rat hepatocytes, in
order to assess the inter-species differences and the fea-
sibility of direct, cross-species extrapolation. Specifically,
the comparison focused on major intracellular processes
that influence the different metabolizing rates between
these two species. First, the TK modeling formulation of
Easterling et al. [34] was parameterized using data from
Styblo et al. [51]. Although, a direct comparison is not
Stamatelos et al. BMC Systems Biology 2011, 5:16
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tures, a subset of parameters was selected for compari-
son that describe three major biochemical processes
which account for similar cellular phenomena in both
models. These processes include transport of arsenite
across cellular membrane, methylation of arsenic, and
biotransformation of AS3MT substrate (iAs in the rat
model, and ATG in human TK model). Specific para-
meters used in comparison include (a) normalized activ-
ity of AQP9 (NP), which is defined as the ratio of influx
and efflux of arsenite, (b) normalized activity of AS3MT
(NM), which is defined as the ratio of the corresponding
reaction parameters, and (c) bioavailability of AS3MT
substrate (BMRS), which is defined as the ratio of rates
of hydrolysis and conjugation of iAs for the human
model, and the dissociation constant for the protein
binding of arsenic in the rat model. These parameters
are specified by Equation 26, and are described in
Table 2. Parameters governing the efflux of arsenic were
not compared because there is no direct correspondence
between the modeling formulations.
In order to facilitate direct comparison, approximate
volumes of the cell cultures used in different experi-
ments (per well) were estimated. Hepatocytes were
assumed to have a spherical shape with 25 μm diameter
for both humans and rats [55]. Cellular volumes (Volc)
for human and rat were estimated to be 1.6 and 0.8 μL
respectively, based on the number of cells used in
human hepatocytes experiments (2*10
5)a n dr a th e p a t o -
cytes experiments (10
5) [34,51].
Human TK
NP
k
k
NM (1 )
V
KV o l c
  
NM (2 )
V
K
inf
0
st maxm
mm
nd maxd
m
:
=
=
×
=
d d
ATGint
iAs int
Volc
BMRS
k
k III
×
=
⎧
⎨
⎪
⎪
⎪
⎪
⎪
⎩
⎪
⎪
⎪
⎪
⎪
(26)
Rat TK:
NP
T
KV o l c p
NM (1 ) k
NM (2 )
V
KV o l c
BMR
max
t1
st
3
nd max
m
=
××
=
=
×
S S
k
k
= 2
1
⎧
⎨
⎪
⎪
⎪
⎪
⎩
⎪
⎪
⎪
⎪
Results and Discussion
The semi-mechanistic TK model was parameterized
using the fmincon function in MATLAB and time
course data of arsenicals in human hepatocytes from
Styblo et al. [51]. The parameters are shown in Table 1.
The model was able to capture the three distinct modes
of the time course patterns corresponding to experimen-
t a ld a t a( s h o w ni nF i g u r e4 ,R o w1 ) .I nc o n t r a s t ,t h e
only currently existing cellular level TK model for
arsenic, from Easterling et al. [34], was parameterized
using the same optimization technique and data, but the
model was not able to adequately capture these modes
(shown in Figure 4, Row 2).
The time-course estimates from the TK model show
that initially (within first minutes of exposure) the rate of
influx of AQP9s is substantially higher than the metabo-
lism, thus leading to a fast accumulation of arsenite
inside the cells. Then, the influx is reduced, and metabo-
lism increases, thus leading to a slow decrease in arsenite
levels (till 8 to 9 hours). During this period, MMA pro-
duction appears to be the dominant process, as shown by
higher levels of MMA compared to DMA, attributable to
t h eh i g hr a t eo fM A D Gh y d r o l y s i s .S u b s e q u e n t l y ,t h e
arsenite concentrations decrease at a faster rate, the sec-
ond methylation reaction becomes more significant, and
MADG hydrolysis is inhibited (Equation 9).
Figure 5 shows the dose-response profiles estimated
by the TK model parameterized using Drobna et al.
data [53]. The model explained the dose-response pro-
files in the data, and captured the significant decrease in
DMA amounts at higher arsenite doses. Based on the
sensitivity testing the threshold concentration value of
0.1 μΜ was able to adequately explain the arsenicals
retention and metabolism, as shown in Figure 6.
Threshold values above 0.1 μΜ overestimate the con-
centration of DMA in hepatocytes by one order of mag-
nitude in the low dose region. On the other hand,
threshold values below 0.1 μΜ (e.g. 0.01 μΜ)u n d e r e s t i -
mate the DMA concentration substantially.
Results of the sensitivity analysis showed that the rela-
tive contribution of variance of individual TK model
Table 2 Comparison of selected parameter values
between two hepatocyte-level TK modeling formulations
Kinetic Process Human-Hepatocyte
TK model
Rat-Hepatocyte
TK model
NP - iAs
III 0.38 0.38
NM - 1
st Reaction (1/min) 3.35 0.02
NM - 2
nd Reaction (1/min) 147.06 0.17
Biotransformation - 1
st MRS 0.0008 33.33
The two formulations are developed based on data of arsenic uptake and
biotransformation in human and rat hepatocytes (NP: Normalized AQP9
activity, NM: Normalized AS3MT activity, MRS: Methylation Reaction Substrate).
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Page 9 of 15parameters varied significantly across different doses of
arsenite. As shown in Figure 7A, at low doses (0.1 μΜ),
the transport parameter k0 (Parameter 19) contributes
most to the variance in intracellular MMA levels. This
agrees with Easterling et al. [34], who reported that the
transport parameters are the most significant in relation
to intracellular concentration of arsenicals. On the other
hand, at higher doses, the parameters related to intracel-
lular biotransformation of MMA are the most influen-
tial. For 1 μMd o s eo fi A s
III the most significant
parameters are koxm (Parameter 5), fGSHm (Parameter
10), k
MMAIII
int (Parameter 7) and Kmt2 (Parameter 15).
The first three parameters (Parameters 5, 10, and 7)
directly influence oxidation and glutathione conjugation
reactions involving MMA
III, whereas the Michaelis
constant (Parameter 15) controls the activity of MRPs
that efflux MADG from the cells. At high doses,
induced antioxidant response of hepatocytes to arsenic
leads to increased production of GSH and MRPs in the
cells, leading to higher production of MADG, which can
be readily effluxed via membrane-associated proteins.
On the other hand, when the oxidation reaction is
dominant (koxm; Parameter 5), it results in higher pro-
duction of MMA
V, which becomes accumulated in the
cells, leading to overall increase in intracellular MMA
levels.
Figure 7B shows sensitivity analysis results for intra-
cellular DMA levels. Similar to results from sensitivity
analysis of MMA levels (Figure 7A), the transport para-
meter k0 (Parameter 19) is the most influential
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Figure 4 Predicted time course profiles of arsenicals in human hepatocytes using two TK model formulations. The top row shows
estimates from the TK model presented here, while the bottom row shows estimates from the TK model formulated using the Easterling et al.
[34] approach. The left column shows intracellular levels of iAs
III, total MMA, and total DMA, while the right column shows corresponding
extracellular levels. Experimental data are from Styblo et al. [51] (exposures to 0.1 μM arsenic for 2 days).
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Page 10 of 15parameter at low doses (0.1 μΜ). For 1 μMd o s e ,D M A
production is significantly influenced primarily by fGSHd
(Parameter 13), which affects the rate of DMAG hydro-
lysis. Furthermore, the oxidation reaction is not impor-
tant in the case of DMA levels, because DMA transport
across the cellular membrane is much faster compared
to MMA transport [56]. This is also corroborated by the
relative values of corresponding transport parameters
for MMA and DMA (fd >> fm,,a ss h o w ni nT a b l e1 ) ,
and by the findings of Styblo et al. [51].
Figure 7C shows sensitivity analysis results for intra-
cellular iAs
III levels. At low doses (0.1 μΜ), the TSIs of
most parameters are close to 1, indicating very high
contributions. This unusual finding can be attributed to
large interaction effects among multiple model para-
meters on the model output (i.e. binary interactions
terms such as Dij,, and tertiary interaction terms such as
Dijk). This was verified by computing first-order sensitiv-
ity indices, which account for contribution of each indi-
vidual parameter (Di) to the output variance without
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Figure 5 Predicted dose-response profiles in human hepatocytes using the cellular level human TK model. The left panel shows total
amounts (in hepatocytes and the medium) of iAs
III, MMA and DMA. The right panel shows corresponding intracellular levels. Experimental data
are from Drobna et al. [53] for hepatocytes from a 63 year old white female.
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Figure 6 Sensitivity testing of TK model predictions for varying assumptions of threshold levels. The left panel shows total amounts (in
hepatocytes and the medium) of DMA, while the right panel shows intracellular levels of DMA. Experimental data are from Drobna et al. [53] for
hepatocytes from a 63 year old white female.
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Page 11 of 15taking into account higher-order interactions [57,58];
these indices for all parameters were low (< 0.1) at low
doses (results not shown). At higher doses, k ATGint
(Parameter 1) and k
iAsIII
int (Parameter 6) are the most
influential. Both these parameters correspond to rate
constants in the bidirectional reaction of ATG with
iAs
III (glutathione conjugation of arsenite and ATG
hydrolysis).
A fundamental hypothesis in this modeling formula-
tion that allows the capturing of the dose-response pro-
files of arsenic retention and methylation across doses
(Figure 5), is the introduction of threshold-dependent
non-linear ("switch-like”) mechanisms in the metabolic
network due to oxidative stress (TR inactivation). This
assumption is based on findings that signaling motifs
exhibit biological switches under a narrow range of
endogenous or exogenous stimuli [59]. This is often
described by a Hill equation with a large Hill coefficient
(e.g., kinase cascades [60] and nuclear-receptor pathways
[61,62]). The large Hill coefficient for inhibition of
MADG hydrolysis (Table 1 - Parameter 8) points to
potential “switch-like” behavior of the activation of Nrf2
due to arsenic-mediated oxidative stress [32].
The parametric comparison between human and rat
hepatocyte TK models for arsenic, presented in Table 2,
provides insight into factors that affect arsenic metabo-
lism in hepatocytes. Specifically, the AS3MT activity is
found to be not a significant factor. Rats have been
reported to be much faster metabolizers of arsenic than
humans [51], but based on this study this is attributed
to other factors. Specifically, in the rat-hepatocyte TK
model (Figure 1), the protein-bound arsenite (p-iAs) is
biotransformed to iAs (substrate of methylation
reaction) at a much higher rate (five orders of magni-
tude) compared to the biotransformation of iAs
III to
ATG (substrate of methylation reaction) of the human-
hepatocyte TK model (Figure 3). This variability could
be influenced by polymorphisms related to GSH pro-
duction in hepatocytes [63] or availability of thiol-con-
taining proteins to interact with AS3MT [28].
This work demonstrates the development of a proto-
type semi-mechanistic toxicokinetic (TK) model for
arsenicals in human hepatocytes introducing features
such as cooperativity and “switch-like” antioxidant
response. Even though this model is not directly applic-
able to in vivo systems as a standalone formulation, it
can be applied to inform macroscopic metabolism-
related parameters in the PBTK model. On the other
hand, more experimental studies on arsenicals in human
hepatocytes will substantially improve model structure
and can help in characterizing inter-individual variability
in arsenic metabolism. Currently, the Styblo et al. study
[ 5 1 ]i st h eo n l ys t u d yi nt h ea u t h o r s ’ knowledge that
reports time course profiles of arsenic methylation in
human hepatocytes. Furthermore, significant uncertain-
ties exist in experimental data due to the limitations of
widely used techniques such as hydride generation-
atomic absorption spectroscopy (HG-AAS) and high
performance liquid chromatography-inductively coupled
plasma-mass spectrometry (HPLC-ICP-MS), where glu-
tathione conjugated arsenic species ATG and MADG
have been reported to be degraded to iAs
III and MMA
III
during the speciation analysis in the bile of rats exposed
to arsenic [64,65].
This cellular-level TK model is based on an arsenic
biotransformation pathway where arsenic-GSH adducts
(ATG, MADG) are substrates for the respective
1 2 3 4 5 6 7 8 9 1 0 1 11 21 31 41 5 1 61 71 81 92 0 2 12 22 32 42 5 2 62 72 82 93 0 3 13 23 33 43 5 3 63 73 83 94 0 4 14 24 3
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Figure 7 Sensitivity analysis of intracellular MMA, DMA and iAs
III estimates. Total Sensitivity Indices (TSI) of TK model parameters with
respect to intracellular MMA (A), DMA (B) and iAs
III (C) levels for three dose scenarios: 0.1 μM - top, 1 μM - bottom left, 10 μΜ - bottom right.
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Page 12 of 15methylation reactions [27,28]. It should be pointed out
that arsenic can be efficiently methylated even in the
absence of GSH [49,66], indicating that arsenic-GSH
complexes need not be major species in the methylation
of arsenic. On the other hand, the explicit consideration
of arsenic-GSH complexes allows the description of a
hysteresis behavior associated with methylation reactions
and the stimulating role of GSH in these processes
(Equations 7-8); so, this mechanism has been selected in
t h i sm o d e l .I ts h o u l db en o t e dt h a ti ti sb e y o n dt h e
scope of this manuscript to comparatively evaluate the
different arsenic biotransformation mechanisms.
Clearly it is, in principle, possible to incorporate into
this cellular level TK model both the oxidative and
reductive mechanisms as individual pathways. However,
currently available experimental data are not adequate
for estimating the relative contributions of each path-
way. Development of improved experimental techniques
for quantifying binding of arsenicals to GSH and thiol-
containing proteins will allow the estimation of the
relative contribution of each pathway. Since AS3MT
coexists in hepatocytes with a number of competing ele-
ments that affect its action, its activity should be deter-
mined based on the availability of each of these
elements. For instance, to study the effectiveness of the
oxidative mechanism, it is possible to knock out GSH
biosynthesis in hepatocytes by interfering with the activ-
ity of Glutamate-Cysteine Ligase (GCL) [67], and expos-
ing them to various doses of arsenite. Such data sets can
be used to estimate AS3MT activities along the two
competing reaction pathways; this type of information is
necessary in order to extend the mathematical formula-
tion of the model described here to include both com-
peting methylation pathways.
Parameter identification is an important issue in com-
putational biology since most of the models involve
more parameters than the available data. The TK model
was parameterized using data on total arsenic of three
species (iAs, MMA, DMA) and it was able to capture
the modes of arsenic retention and methylation in
human hepatocytes, but was not able to exactly capture
the time-course profiles from the experimental data. In
order to reduce the uncertainty associated with this
issue, sensitivity analysis and testing were conducted as
a means to identify the relative impact of each para-
meter on model predictions [68]. Additional time-course
data (either on intermediate species or under more
exposure/dose conditions) can improve model perfor-
mance, and can help obtain additional mechanistic
insights into the dynamics of arsenicals in hepatocytes.
Conclusions
A cellular-level TK model was developed based on a
recently proposed pathway of arsenic biotransformation.
This model can describe uptake, retention and clearance
of arsenicals in human hepatocytes using a semi-
mechanistic approach. It highlights the key biological
processes that influence arsenic metabolism by explicitly
modelling the metabolic network of GSH-adducts for-
mation [27]. Moreover, comparison of the model struc-
ture and parameters with a rat-hepatocyte TK model
[34] highlights the relative roles of different metabolic
reactions in the methylation of arsenic. Ongoing work
involves incorporating this cellular-level semi-mechanis-
tic TK model as a module within a whole-body PBTK
model of arsenic [44], in order to improve the PBTK
model parameterization and its predictions [69].
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